Table 1

Baseline characteristics of patients, total n=77

Rituximab-treated patientsEculizumab-treated patientsP value
Patients, n5720
Age at baseline, years, mean (SD)46.5 (17.1)45.4 (15.2)0.791
Age at diagnosis, years, mean (SD)40.8 (18.2)36.5 (12.2)0.351
Early onset MG, n (%)36 (63.1)16 (80.0)0.266
Late onset MG, n (%)21 (36.9)4 (20.0)0.266
Female patients, n (%)35 (62.5)12 (54.6)0.610
Disease duration, years, mean (SD)6.3 (4.5)8.8 (6.3)0.068
QMG score at baseline, mean (SD)10.7 (5.1)13.2 (5.2)0.056
MGFA status at maximum severity, n (%)
 I0 (0.0)0 (0.0)0.335
 II16 (28.1)10 (50.0)
 III20 (35.1)5 (25.0)
 IV16 (28.1)3 (15.0)
 V7 (12.2)2 (10.0)
History of thymectomy, n (%)29 (50.8)13 (65)0.308
Confirmed thymoma, n (%)8 (14.0)4 (20.0)0.487
Total number of previous ISTs, median (minimum–maximum)2 (2–3)2 (2–3)0.285
Previous disease modifying therapy, n (%)
 Azathioprine49 (85.9)18 (90.0)0.729
 Mycophenolate26 (45.6)14 (70.0)0.072
 Methotrexate24 (42.1)7 (35.0)0.608
 Cyclosporine7 (12.2)5 (25.0)0.279
Cortisone at baseline, mg, mean (SD)6.0 (10.3)10.4 (12.6)0.121
Number of previous MC, median (minimum–maximum)1 (0–3)1 (0–3)0.971
  • Baseline refers to the first infusion of rituximab or eculizumab. Disease duration was defined as the time between symptom onset and baseline. Patients with rituximab were compared with patients receiving eculizumab by two-sided Student’s t-test (*) or Fisher’s exact test (#). P values are given; significance cut-off was p<0.05.

  • IST, immunosuppressive therapy; MC, myasthenic crisis; MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; QMG, quantitative myasthenia gravis.